BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28825750)

  • 1. Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with
    Baum RP; Singh A; Benešová M; Vermeulen C; Gnesin S; Köster U; Johnston K; Müller D; Senftleben S; Kulkarni HR; Türler A; Schibli R; Prior JO; van der Meulen NP; Müller C
    Dalton Trans; 2017 Oct; 46(42):14638-14646. PubMed ID: 28825750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-Human PET/CT Imaging of Metastatic Neuroendocrine Neoplasms with Cyclotron-Produced
    Singh A; van der Meulen NP; Müller C; Klette I; Kulkarni HR; Türler A; Schibli R; Baum RP
    Cancer Biother Radiopharm; 2017 May; 32(4):124-132. PubMed ID: 28514206
    [No Abstract]   [Full Text] [Related]  

  • 3. Future prospects for SPECT imaging using the radiolanthanide terbium-155 - production and preclinical evaluation in tumor-bearing mice.
    Müller C; Fischer E; Behe M; Köster U; Dorrer H; Reber J; Haller S; Cohrs S; Blanc A; Grünberg J; Bunka M; Zhernosekov K; van der Meulen N; Johnston K; Türler A; Schibli R
    Nucl Med Biol; 2014 May; 41 Suppl():e58-65. PubMed ID: 24360901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application.
    Müller C; Domnanich KA; Umbricht CA; van der Meulen NP
    Br J Radiol; 2018 Nov; 91(1091):20180074. PubMed ID: 29658792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β- radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative.
    Müller C; Zhernosekov K; Köster U; Johnston K; Dorrer H; Hohn A; van der Walt NT; Türler A; Schibli R
    J Nucl Med; 2012 Dec; 53(12):1951-9. PubMed ID: 23139086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical in vivo application of (152)Tb-DOTANOC: a radiolanthanide for PET imaging.
    Müller C; Vermeulen C; Johnston K; Köster U; Schmid R; Türler A; van der Meulen NP
    EJNMMI Res; 2016 Dec; 6(1):35. PubMed ID: 27108447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical investigations and first-in-human application of
    Müller C; Singh A; Umbricht CA; Kulkarni HR; Johnston K; Benešová M; Senftleben S; Müller D; Vermeulen C; Schibli R; Köster U; van der Meulen NP; Baum RP
    EJNMMI Res; 2019 Jul; 9(1):68. PubMed ID: 31346796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclotron production and radiochemical purification of terbium-155 for SPECT imaging.
    Favaretto C; Talip Z; Borgna F; Grundler PV; Dellepiane G; Sommerhalder A; Zhang H; Schibli R; Braccini S; Müller C; van der Meulen NP
    EJNMMI Radiopharm Chem; 2021 Nov; 6(1):37. PubMed ID: 34778932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Head-to-Head Comparison of
    Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
    J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The low-energy β(-) and electron emitter (161)Tb as an alternative to (177)Lu for targeted radionuclide therapy.
    Lehenberger S; Barkhausen C; Cohrs S; Fischer E; Grünberg J; Hohn A; Köster U; Schibli R; Türler A; Zhernosekov K
    Nucl Med Biol; 2011 Aug; 38(6):917-24. PubMed ID: 21843788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor.
    Todorović-Tirnanić M; Kaemmerer D; Prasad V; Hommann M; Baum RP
    Recent Results Cancer Res; 2013; 194():487-96. PubMed ID: 22918778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
    Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
    Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
    Gaertner FC; Beer AJ; Souvatzoglou M; Eiber M; Fürst S; Ziegler SI; Brohl F; Schwaiger M; Scheidhauer K
    Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross section measurement of terbium radioisotopes for an optimized
    Dellepiane G; Casolaro P; Favaretto C; Grundler PV; Mateu I; Scampoli P; Talip Z; van der Meulen NP; Braccini S
    Appl Radiat Isot; 2022 Jun; 184():110175. PubMed ID: 35344829
    [No Abstract]   [Full Text] [Related]  

  • 15.
    Favaretto C; Grundler PV; Talip Z; Landolt S; Sepini L; Köster U; Müller C; Schibli R; Geistlich S; van der Meulen NP
    J Nucl Med; 2023 Jul; 64(7):1138-1144. PubMed ID: 37201956
    [No Abstract]   [Full Text] [Related]  

  • 16. Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.
    Nakamoto Y; Sano K; Ishimori T; Ueda M; Temma T; Saji H; Togashi K
    Ann Nucl Med; 2015 Jul; 29(6):512-8. PubMed ID: 25894056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of terbium-152 by heavy ion reactions and proton induced spallation.
    Allen BJ; Goozee G; Sarkar S; Beyer G; Morel C; Byrne AP
    Appl Radiat Isot; 2001 Jan; 54(1):53-8. PubMed ID: 11144253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Dynamic 68Ga-DOTA-D-Phe1-Tyr3-Octreotide PET/CT in Patients With Hepatic Metastases of Neuroendocrine Tumors.
    Sänger PW; Freesmeyer M
    Clin Nucl Med; 2016 Jun; 41(6):447-53. PubMed ID: 26859210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-in-Humans Application of
    Baum RP; Singh A; Kulkarni HR; Bernhardt P; Rydén T; Schuchardt C; Gracheva N; Grundler PV; Köster U; Müller D; Pröhl M; Zeevaart JR; Schibli R; van der Meulen NP; Müller C
    J Nucl Med; 2021 Oct; 62(10):1391-1397. PubMed ID: 33547209
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study.
    Pfeifer A; Knigge U; Mortensen J; Oturai P; Berthelsen AK; Loft A; Binderup T; Rasmussen P; Elema D; Klausen TL; Holm S; von Benzon E; Højgaard L; Kjaer A
    J Nucl Med; 2012 Aug; 53(8):1207-15. PubMed ID: 22782315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.